A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy

In brief

The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.

Key facts

Study ID

NCT06890611

Run by

Eli Lilly and Company

People needed

125

Starts

2025-03-25

Expected to finish

2025-09-26

Last updated by the study team

2025-10-09

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Are considered healthy as determined by medical evaluation including medical history and physical examination
• Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive

You may not qualify if…

• Have current or a history of pancreatitis or hepatitis
• Have a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening
• Have uncontrolled high blood pressure
• Have taken medications or alternative remedies to promote weight loss within 3 months prior to screening

Where it is running

• Fortrea Clinical Research Unit — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.